表紙
市場調査レポート

サルコイドーシス : パイプライン分析

Sarcoidosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 200487
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
サルコイドーシス : パイプライン分析 Sarcoidosis - Pipeline Review, H1 2016
出版日: 2016年03月16日 ページ情報: 英文 42 Pages
概要

リンパ節や肺、肝臓、眼球、皮膚などの組織の隆起・膨張のことをサルコイドーシスと呼びます。サルコイドーシスは人体のあらゆる組織に作用することが可能で、最初は肺やリンパ節の上の肉芽腫として現れます。サルコイドーシスの要因についてはまだよく分かっていませんが、呼吸困難やせき、皮膚発疹、顔面・腕・脛上の赤い隆起(結節性紅斑)、目の炎症などが主な共通する兆候として挙げられています。また体重損失や倦怠感、寝汗、高熱なども伴います。治療の主な目的は、肺やその他の感染した人体組織の働きを保ち、症状を緩和させることにあります。現在、コルチコステロイド薬剤が炎症・肉芽腫形成に対して用いられる他、クロロキン、D-ペニシラミン、クロランブシル、メトトレキサートなども利用されます。

当レポートでは、世界各国でのサルコイドーシス(類肉腫症)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

サルコイドーシスの概要

治療薬の開発

  • サルコイドーシス向けパイプライン製品:概要
  • サルコイドーシス向けパイプライン製品:比較分析

各企業で開発中のサルコイドーシス治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

サルコイドーシス治療薬:開発中の製品の一覧(企業別)

サルコイドーシス治療薬の開発に従事している企業

  • Araim Pharmaceuticals Inc.
  • Celgene Corporation
  • FirstString Research, Inc.
  • Novartis AG
  • PharmaIN Corporation

サルコイドーシス:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • ABS-11
  • apremilast
  • canakinumab
  • CC-220
  • cibinetide
  • eprodisate disodium
  • PGC-VIP
  • Synthetic Peptide for Sarcoidosis

サルコイドーシス治療薬:最新の薬剤プロファイル

サルコイドーシス治療薬:開発が休止状態の製品

サルコイドーシス治療薬:開発が中止された製品

サルコイドーシス関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7796IDB

Summary

Global Markets Direct's, 'Sarcoidosis - Pipeline Review, H1 2016', provides an overview of the Sarcoidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
  • The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects
  • The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sarcoidosis Overview
  • Therapeutics Development
    • Pipeline Products for Sarcoidosis - Overview
  • Sarcoidosis - Therapeutics under Development by Companies
  • Sarcoidosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Sarcoidosis - Products under Development by Companies
  • Sarcoidosis - Companies Involved in Therapeutics Development
    • Araim Pharmaceuticals, Inc.
    • FirstString Research, Inc.
    • PharmaIN Corporation
  • Sarcoidosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABS-11 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eprodisate disodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Sarcoidosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sarcoidosis - Recent Pipeline Updates
  • Sarcoidosis - Dormant Projects
  • Sarcoidosis - Discontinued Products
  • Sarcoidosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA
      • Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy
      • Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring
      • Oct 10, 2013: Araim Pharmaceuticals' ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sarcoidosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Sarcoidosis - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
  • Sarcoidosis - Pipeline by FirstString Research, Inc., H1 2016
  • Sarcoidosis - Pipeline by PharmaIN Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Sarcoidosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Sarcoidosis - Dormant Projects, H1 2016
  • Sarcoidosis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Sarcoidosis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top